Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 14 Week Randomized Parallel Group Placebo-Controlled Double-Blind Multicentre Study Of Fesoterodine 8 Mg In Overactive Bladder Patients With Sub-Optimal Response To Tolterodine 4 Mg Extended Release (ER).

NCT01302054 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01302054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01302054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 14 Week Randomized Parallel Group Placebo-Controlled Double-Blind Multicentre Study Of Fesoterodine 8 Mg In Overactive Bladder Patients With Sub-Optimal Response To Tolterodine 4 Mg Extended Release (ER).
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2011
Completion date
May 31, 2012
Enrollment
990 (actual)
Sites
176

Conditions

As the registry lists them; a condition with its own page is linked.

urinary bladder, overactive